Literature DB >> 18489493

Health state utilities in latent and active tuberculosis.

Na Guo1, Carlo A Marra, Fawziah Marra, Susanne Moadebi, R Kevin Elwood, J Mark Fitzgerald.   

Abstract

BACKGROUND: Tuberculosis (TB) remains a major public health threat worldwide. Numerous cost-effectiveness analyses of TB screening and treatment strategies have been recently published, but none have utilized quality-adjusted life-years as recommended because of the lack of utilities for TB health states.
OBJECTIVE: To characterize and compare utility scores from either active TB or latent TB infection (LTBI) participants.
METHODS: Consenting patients attending a population-based screening and treatment clinic were administered the Short Form 36 (SF-36), the Health Utilities Index 2/3 (HUI2/3), and a general health visual analog scale (VAS) along with demographic questions. SF-36 scores were converted to Short Form 6D (SF-6D) utility scores using an accepted algorithm. Utility results were compared across scales, and construct validity was assessed.
RESULTS: A total of 162 TB patients (78 LTBI and 84 active TB) with available SF-36 and all four utility scores (Health Utilities Index 2, Health Utilities Index 3, SF-6D and VAS) were included in the analysis. Those with active TB had significantly lower SF-36 and utility scores than those with LTBI. Although all appeared to exhibit construct validity, the HUI2/3 and the VAS appeared to have significant ceiling effects, whereas the SF-6D had significant floor effects.
CONCLUSIONS: Health state utility values for active TB and LTBI have been determined using different instruments. The three measures did not generate identical utility scores. The HUI2/3 was limited by ceiling effects, whereas the SF-6D appeared to display floor effects.

Entities:  

Mesh:

Year:  2008        PMID: 18489493     DOI: 10.1111/j.1524-4733.2008.00355.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  44 in total

1.  Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States.

Authors:  H W Choi; K Miele; D Dowdy; M Shah
Journal:  Int J Tuberc Lung Dis       Date:  2013-10       Impact factor: 2.373

2.  Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.

Authors:  D Shepardson; S M Marks; H Chesson; A Kerrigan; D P Holland; N Scott; X Tian; A S Borisov; N Shang; C M Heilig; T R Sterling; M E Villarino; W R Mac Kenzie
Journal:  Int J Tuberc Lung Dis       Date:  2013-12       Impact factor: 2.373

3.  Cost-effectiveness analysis of interventions for tuberculosis control: DALYs versus QALYs.

Authors:  R Diel; N Lampenius
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

4.  Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children.

Authors:  Benjamin L Laskin; Jens Goebel; Jeffrey R Starke; Daniel P Schauer; Mark H Eckman
Journal:  Am J Kidney Dis       Date:  2012-07-10       Impact factor: 8.860

5.  The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease.

Authors:  Nicolas A Menzies; Sourya Shrestha; Andrea Parriott; Suzanne M Marks; Andrew N Hill; David W Dowdy; Priya B Shete; Ted Cohen; Joshua A Salomon
Journal:  Epidemiology       Date:  2022-01-01       Impact factor: 4.822

6.  Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.

Authors:  David P Holland; Gillian D Sanders; Carol D Hamilton; Jason E Stout
Journal:  Am J Respir Crit Care Med       Date:  2009-03-19       Impact factor: 21.405

7.  Health-related quality of life of inpatients and outpatients with TB in rural Malawi.

Authors:  Y Jo; I Gomes; H Shin; A Tucker; L G Ngwira; R E Chaisson; E L Corbett; D W Dowdy
Journal:  Int J Tuberc Lung Dis       Date:  2020-11-01       Impact factor: 2.373

8.  Factors associated with health-related quality of life among pulmonary tuberculosis patients in Manila, the Philippines.

Authors:  Shoichi Masumoto; Taro Yamamoto; Akihiro Ohkado; Shoji Yoshimatsu; Aurora G Querri; Yasuhiko Kamiya
Journal:  Qual Life Res       Date:  2013-11-22       Impact factor: 4.147

9.  Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease.

Authors:  Mike van der Have; Bas Oldenburg; Herma H Fidder; Tim D G Belderbos; Peter D Siersema; Martijn G H van Oijen
Journal:  Dig Dis Sci       Date:  2013-08-15       Impact factor: 3.199

Review 10.  Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.

Authors:  Suzanne M Marks; Sundari R Mase; Sapna Bamrah Morris
Journal:  Clin Infect Dis       Date:  2017-06-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.